The strong revenue beat and narrowing losses support the company's path to profitability. Key catalysts ahead include the AXS-12 PDUFA decision in May 2027 and multiple Phase 3 readouts in 2027. Monitor prescription trends and payer coverage updates for continued commercial momentum.
Drugs in focus
AXSM drug pipeline →AXS-12
● Neutral Named in this press release- Impact
- Phase
- Filed/PDUFA (NDA accepted; Phase 3 completed)
- Time to market
- NDA is already under FDA review; a decision is due by May 1, 2027, with commercial launch in 2027 if approved — roughly 9 months to the binary.
- Next catalyst
- PDUFA date · May 1, 2027 165d
What to watchWatch for FDA communications ahead of the May 1, 2027 PDUFA, e.g., any newly scheduled advisory committee, labeling discussions, or a potential priority-review/timing change, and treat AXS-12 approval as incremental upside on top of the AUVELITY (incl. Alzheimer's agitation) and SUNOSI commercial story rather than the stock's primary thesis. Near-term share moves are more likely tied to quarterly product sales and the Alzheimer's agitation launch than to AXS-12, since its binary is ~9 months out.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 2 $136.01entry
- T+1 · 14d ago +2.65%α +2.35% · $139.61
- T+5 · 8d ago −1.51%α −1.59% · $133.96
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Axsome Therapeutics reported Q3 2026 net product revenue of $259.7M, 52% YoY growth, beating the $249.2M consensus. Net loss narrowed to $12.9M ($0.25 per share) from $47.2M ($0.94 per share) a year ago, significantly better than the consensus EPS loss of $0.64. The company highlighted strong Auvelity and Sunosi prescription trends and initiated the Phase 3 SUMMIT trial for AXS-05 in smoking cessation.
Key Financial Metrics
Key Facts
- Q3 2026 total net product revenue $259.7M, up 52% YoY from $171.0M, above consensus $249.2M.
- Net loss $12.9M ($0.25 per share) vs $47.2M ($0.94 per share) YoY, beating consensus EPS loss of $0.64.
- Auvelity net product sales $207.6M, up 53% YoY; total prescriptions ~302,000, up 40% YoY.
- Sunosi net product revenue $48.2M, up 47% YoY; prescriptions up 15% YoY.
- Symbravo net product sales $3.9M, up 88% YoY; prescriptions up 382% YoY.
- Cash and equivalents $313.9M at Sep 30, 2026; company believes cash sufficient to fund operations into cash flow positivity.
- Phase 3 SUMMIT trial of AXS-05 for smoking cessation initiated; topline results expected 2H 2027.
- AXS-12 NDA for narcolepsy/cataplexy under FDA review with PDUFA date May 1, 2027.
Financial Impact
Revenue beat consensus by $10.5M (4.2%); EPS beat consensus by $0.39 (60.9%); net loss narrowed significantly YoY.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| AUVELITY | $207.6M | +52.5% |
| SUNOSI | $48.2M | +47.0% |
| SYMBRAVO | $3.9M | +85.7% |
Risk Factors
- Company remains unprofitable with accumulated deficit of $1.43B; path to cash flow positivity depends on sustained revenue growth.
- SG&A expenses rose 35% YoY to $203.1M, outpacing revenue growth; operating leverage not yet demonstrated.
- Pipeline programs are early-stage; regulatory and clinical trial risks for AXS-12, AXS-05, and solriamfetol candidates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3392981 |
Track record
26 reports on AXSM
6 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Viewing Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers